Academic Journals Database
Disseminating quality controlled scientific knowledge

Benign prostatic hyperplasia: An overview of existing treatment

Author(s): Dhingra Neelima | Bhagwat Deepak

Journal: Indian Journal of Pharmacology
ISSN 0253-7613

Volume: 43;
Issue: 1;
Start page: 6;
Date: 2011;
Original page

Keywords: Benign prostatic hyperplasia | prostate | treatment | α1-adrenergic antagonist | 5α-reductase inhibitors

Benign prostatic hyperplasia (BPH) is the most common condition in aging men, associated with lower urinary tract symptoms (LUTS). A better understanding of the prostate physiology, function, and pathogenesis has led to the development of promising agents, useful in the management of LUTS in men. The specific approach used to treat BPH depends upon number of factors like age, prostrate size, weight, prostate-specific antigen level, and severity of the symptoms. 5α-reductase inhibitors decrease the production of dihydrotestosterone within the prostate, which results in decreased prostate volume, increased peak urinary flow rate, improvement of symptoms, decreased risk of acute urinary retention, and need for surgical intervention. α1 -adrenergic receptor (α1 -AR) antagonists decrease LUTS and increase urinary flow rates in men with symptomatic BPH, but do not reduce the long-term risk of urinary retention or need for surgical intervention. Clinical efficacy of either 5α-reductase inhibitor or α1 -AR antagonist has been further improved by using combination therapy; however, long-term outcomes are still awaited. Many more potential new therapies are under development that may improve the treatment of BPH. This article gives a brief account of rationale and efficacy of different treatment options presently available in the management of BPH.
Save time & money - Smart Internet Solutions      Why do you need a reservation system?